Updated on 12.02.2026|14:40 PM
Accretion Nutraveda Limited is set to open its Initial Public Offering (IPO) for subscription on Tuesday, January 27, 2026 and close on January 30, 2026. It is a Gujarat-based Contract Development and Manufacturing Organization (CDMO) specializing in ayurvedic and nutraceutical products.
You can track the details of all the upcoming and live IPOs at our IPO Calendar hub page which is updated regularly with all the key details.
Operating from a WHO-GMP and ISO-certified facility in Sanand, the company manufactures a diverse range of tablets, capsules, and oral liquids.
With a price band fixed at ₹122 to ₹129 per equity share, the issue aims to raise approximately ₹24.77 Crores to fund automation, capacity expansion, and working capital needs.
In this article, you will find Accretion Nutraveda IPO GMP today, price band, and a detailed review. For allotment status and subscription status you can visit our IPO subscription status and IPO allotment status hub pages which are updated regularly.
Briefs of Accretion Nutraveda IPO Details
- Price Band: ₹122 – ₹129 per equity share
- IPO Open / Close Dates: January 27, 2026 – January 30, 2026
- Lot Size: 1,000 Shares (Retail Minimum Investment: ₹1,29,000)
- Issue Size: 19,20,000 Equity Shares (approx. ₹24.77 Crores)
- Fresh Issue / OFS: 100% Fresh Issue
- Registrar: Kfin Technologies Ltd.
- Listing Exchange: BSE SME
As Kfin technologies limited is the registrar of this IPO, and often the investors have queries related to allotment status, credit of shares and similar things which you can find in our detailed guide on Kfintech allotment status guide.
WHAT IS THE Accretion Nutraveda IPO GMP Today?
You can check the GMP of this and other issues at our GMP Today hub page which is updated regularly.
Note: The Grey Market Premium (GMP) varies daily based on market demand. It is an unofficial indicator and is not regulated by SEBI, NSE, or BSE. Investors should not rely solely on GMP for investment decisions.
Listing Updates
| Type | Issue Price | Open | Gain/loss % |
| Lisiting | 129.00 | 191.00 | 48.06 |
What Are The Important Accretion Nutraveda IPO Dates & Allotment Schedule?
- IPO Open Date: Tuesday, January 27, 2026
- IPO Close Date: Friday, January 30, 2026
- Basis of Allotment Date: Monday, February 2, 2026
- Refund Initiation Date: Tuesday, February 3, 2026
- Credit of Shares: Tuesday, February 3, 2026
- Listing Date: Wednesday, February 4, 2026
What Are The Objectives of Accretion Nutraveda IPO?
The company proposes to utilize the Net Proceeds from the Fresh Issue towards the following strategic goals:
- Capital Expenditure: A significant portion is allocated for the purchase of machinery for automation at the existing unit (₹4.22 Crores) and setting up a new manufacturing facility (₹8.03 Crores).
- Working Capital: To fund incremental working capital requirements of ₹5.50 Crores arising from business growth.
- General Corporate Purposes: To meet general corporate exigencies.
How is The Financial Performance of Accretion Nutraveda?
The following table summarizes the financial performance of the company based on the Restated Financial Statements.
(Figures in ₹ Crores)
| Particulars | Period Ended 30 Sep 25 | Period Ended 31 Mar 25 | Period Ended 31 Mar 24 | Period Ended 31 Mar 23 |
Total Income | 14.07 | 16.06 | 5.20 | 3.07 |
Profit After Tax | 2.33 | 2.61 | 0.82 | 0.28 |
EBITDA | 3.29 | 3.65 | 1.21 | 0.59 |
Total Borrowing | 4.43 | 3.86 | 2.17 | 1.97 |
Assets | 16.35 | 10.86 | 4.64 | 4.06 |
Source: RHP
Financial Analysis:
Total Income:
The company has demonstrated exponential growth, with Total Income jumping from ₹5.20 Crores in FY24 to ₹16.06 Crores in FY25. The momentum continued in the first half of FY26 (ended Sep 30, 2025), where the company achieved ₹14.07 Crores, nearly matching the entire previous year's revenue in just six months.
Profit After Tax (PAT):
Profitability has surged alongside revenue, with PAT rising to ₹2.61 Crores in FY25 compared to ₹0.82 Crores in FY24. The net margins have remained healthy, driven by better capacity utilization and economies of scale.
EBITDA:
The company reported an EBITDA of ₹3.29 Crores for the half-year ended September 2025, maintaining robust margins of over 23%. This indicates strong operational efficiency in its manufacturing processes.
Total Borrowing:
Debt levels have increased to ₹4.43 Crores as of September 2025 to support the rapid expansion and working capital needs. The IPO proceeds are expected to stabilize the leverage position by funding future capex through equity.
Assets:
The asset base expanded significantly to ₹16.35 Crores in September 2025. This increase is largely attributed to a buildup in inventories and trade receivables, reflecting the working capital intensity required to support the sharp rise in order volumes.
What Are the P/E Ratio and Peer Comparison?
Based on its Fiscal Year 2025 earnings per share (EPS) of ₹7.19, the IPO is priced at a Price-to-Earnings (P/E) multiple of approximately 17.94x at the upper end of the price band (₹129).
P/E Ratio = ₹129(Price) / ₹7.19(Earnings Per Share)
P/E Ratio ≈ 17.94x
Peer Comparison Table (Data as of Sep 30, 2025):
| Company | P/E Ratio | RoNW (%) |
Accretion Nutraveda | 17.94 | 56.50 |
| Walpar Nutritions Ltd | 3.30 | 6.24 |
| Influx Healthtech Ltd | 46.99 | 11.10 |
*Annualized RoNW based on stub period data.
Analysis:
Accretion Nutraveda is entering the market at a P/E multiple of approximately 17.94x. While this is higher than Walpar Nutritions (3.30x), it is significantly lower than Influx Healthtech (46.99x).
Notably, Accretion boasts a superior Return on Net Worth (RoNW) of over 56% (annualized for H1 FY26), which far exceeds its peers, suggesting highly efficient capital utilization.
What is The Industry Outlook Accretion Nutraveda Limited?
Growth Potential:
The Indian nutraceuticals market is projected to grow at a robust pace, driven by a shift towards preventive healthcare and immunity-boosting products post-pandemic.
Market Trends:
There is a rising trend of outsourcing manufacturing to specialized CDMOs like Accretion, as brands focus on marketing while ensuring product quality through certified partners.
What Are The Strengths and Risks of Accretion Nutraveda IPO?
Strengths:
- Explosive Growth: The revenue and profit growth over the last 18 months has been exceptional, with FY25 revenue tripling year-on-year.
- High Efficiency: A Return on Net Worth (RoNW) exceeding 48% in FY25 indicates excellent management of shareholder funds.
- Expansion Focus: The IPO funds are clearly earmarked for automation and new capacity, providing visibility for future volume growth.
Risks:
- Negative Cash Flow: The company reported negative operating cash flows in recent periods due to funds being tied up in working capital.
- Geographic Concentration: A massive 96% of revenue in the recent period came from Gujarat, exposing the company to regional risks.
- Legal Issues: Pending legal matters regarding a "not of standard quality" drug sample and SEBI penalties on a group company could pose reputational risks.
Key Considerations for Investors
This analysis is neutral and for informational purposes only.
- Valuation: At ~17.9x P/E, the pricing appears reasonable given the high growth rate, especially when compared to higher-valued peers in the sector.
- Cash Flow Management: Investors should monitor the company's ability to turn its accounting profits into operating cash flow, given the recent negative trends.
- Customer Concentration: With top 5 customers contributing over 75% of revenue, the loss of a key client could impact financials.
Key Takeaways
- IPO Price: ₹129 per share (Upper Band).
- Min Investment: ₹1,29,000 (1,000 Shares).
- Allotment Date: February 2, 2026
- Listing: BSE SME Platform on February 4, 2026.
FAQs on Accretion Nutraveda IPO
What is Accretion Nutraveda IPO GMP today?
The GMP is a dynamic market sentiment indicator. You can check the details of gmp at our ipo gmp today platform which is updated regularly.
What is Accretion Nutraveda IPO price band?
The price band has been fixed at ₹122 to ₹129 per equity share.
What is Accretion Nutraveda IPO allotment date?
The allotment of shares is expected to be finalized on Monday, February 2, 2026.
How to check Accretion Nutraveda IPO allotment status?
The allotment status can be checked on the website of Kfin Technologies Ltd. or via the BSE IPO allotment page once declared.
What is Accretion Nutraveda IPO listing date?
The shares are tentatively scheduled to list on the BSE SME platform on Wednesday, February 4, 2026.
Investment Perspective on Accretion Nutraveda IPO
Accretion Nutraveda presents a high-growth opportunity in the wellness sector with impressive return ratios. However, risks related to negative cash flows and geographic concentration should be carefully weighed against the attractive valuation and expansion plans.
Disclaimer:
This article is strictly for educational purposes. Please consult a SEBI-registered investment advisor before making any investment decisions.
